Olpha

EN Texto en inglés Aún no hay artículo en tu idioma: extracto en inglés.

JSC Olpha (formerly JSC Olainfarm) is a Latvian pharmaceutical company and drug manufacturer. In June 2024, Olainfarm announced a rebranding to Olpha. The company traces its origins to the Olaine Chemical-Pharmaceutical Plant. Its first synthesis of furagin was carried out on 10 October 1972, a date the company identifies as the start of its operations under the name Olaines ķīmiski-farmaceitiskā rūpnīca. Olainfarm produces over 60 final dosage forms, 25 active pharmaceutical ingredients and 20 intermediates. Their key areas of specialization in final dosage forms include neurology (cholinesterase inhibitors, anxiolytics, psychostimulants, nootropics), cardiology (antiarrhythmics, energy metabolism enhancers), infectology (original nitrofurantoine derivatives and antivirals) and allergology (fast acting antihistamines). Olainfarm is certified in accordance with the requirements of the EU GMP for APIs and FDFs, the U.S. cGMP for certain APIs (FDA), TGA for FDFs (Australia), CEP for certain APIs, ISO 14001 Environmental Management System and ISO 17025 Laboratory Management System.